This extension of the bridge loan agreement will provide IRRAS an additional MSEK 10 in funding to cover its working capital needs until the completion of the company's ongoing rights issue process, which was approved at an EGM held on Wednesday,
About IRRAS
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in
IRRAS maintains its headquarters in
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172
The information was released for public disclosure, through the agency of the contact person above, on
https://news.cision.com/irras/r/irras-expands-short-term-financing-agreement,c3612086
https://mb.cision.com/Main/16550/3612086/1613123.pdf
(c) 2022 Cision. All rights reserved., source